225Ac-DOTA-LM3 Research for Neuroendocrine Tumors (NETs)
An evidence-based overview of research examining 225Ac-DOTA-LM3 in the context of neuroendocrine tumors (nets). This page synthesizes findings from peer-reviewed literature.
Research Summary
225Ac-DOTA-LM3 is primarily investigated for SSTR-positive neuroendocrine tumors. Phase 1/2 studies from Heidelberg showed 95% disease control rate with 29% partial responses in patients including those refractory to Lu-177 DOTATATE. The antagonist binding mechanism provides superior tumor uptake compared to agonist-based therapies.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. 225Ac-DOTA-LM3 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.